Physician Views snap poll - A long time coming, how do prescribers view Amgen, UCB's Evenity

Amgen and UCB's Evenity - a new treatment option in the US for postmenopausal osteoporosis - has followed a less than straightforward path from clinic to market.

Experts believe, nevertheless, that there is a definite, if defined, market for Evenity, which means the drug could beat analysts' current revenue projections. To get a better understanding of the commercial outlook for Evenity, we are snap-polling potential prescribers with the following questions…

____________

Q. The FDA has approved Evenity (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk of fracture. It is described as "the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture."

In the placebo-controlled FRAME study, treatment with Evenity resulted in a significant reduction of new vertebral fracture at 12 months versus placebo. This persisted through the second year in women who received Evenity during the first year and transitioned to denosumab compared to those who transitioned from placebo to denosumab. In addition, Evenity significantly increased bone mineral density (BMD) at the lumbar spine, total hip and femoral neck compared to placebo at 12 months. Following the transition from Evenity to denosumab at month 12, BMD continued to increase through month 24.

In the active-controlled ARCH study, treatment with Evenity for 12 months followed by 12 months of alendronate significantly reduced the incidence of new vertebral fracture at 24 months. Evenity followed by alendronate significantly reduced the risk of clinical fracture (defined as a composite of symptomatic vertebral fracture and non-vertebral fracture) after a median follow-up of 33 months. Evenity significantly increased BMD at the lumbar spine, total hip and femoral neck at 12 months compared to alendronate. Twelve months of treatment with Evenity followed by 12 months of treatment with alendronate significantly increased BMD compared with alendronate alone.

A full course of EVENITY therapy is 12 monthly doses (via subcutaneous injection) administered by a healthcare provider

Based on your current knowledge of the product, how compelling a new treatment option for postmenopausal osteoporosis do you consider Evenity to be?

Not compelling

Marginally compelling

Moderately compelling

Very compelling

Extremely compelling

-

Q. Evenity has a Boxed Warning in its product label that advises a potential increase in the risk of myocardial infarction (heart attack), stroke and cardiovascular death, and treatment should not be initiated in patients who have had a heart attack or stroke within the preceding year. The most common adverse reactions (≥5 percent) reported with Evenity were arthralgia (joint pain) and headache.

Approval comes with a post-marketing requirement from the FDA to assess the cardiovascular safety of Evenity in women with postmenopausal osteoporosis. The requirement includes a five-year observational feasibility study, potentially followed by a comparative safety study or trial. 

To what extent do you think these factors will limit your adoption of Evenity?

No impact

Marginal impact

Moderate impact

Significant impact

Very significant impact

-

Q. To what extent do you think administration by monthly subcutaneous injection will have a positive impact on your adoption of Evenity?

No impact

Marginal impact

Moderate impact

Significant impact

Very significant impact

-

Q. To what extent do you think the 12-month treatment duration will have a positive impact on your adoption of Evenity?

No impact

Marginal impact

Moderate impact

Significant impact

Very significant impact

-

Q. Also taking into account that Evenity is priced at $1825 per dose, or $21900 for a full 12-month course of injections, to what percentage of women with postmenopausal osteoporosis do you anticipate prescribing this treatment to 12 months post-launch?

____________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.